Articles
Page 2 of 33
-
Citation: Alzheimer's Research & Therapy 2024 16:39
-
Genome-wide association study and polygenic risk scores of retinal thickness across the cognitive continuum: data from the NORFACE cohort
Several studies have reported a relationship between retinal thickness and dementia. Therefore, optical coherence tomography (OCT) has been proposed as an early diagnosis method for Alzheimer’s disease (AD). I...
Citation: Alzheimer's Research & Therapy 2024 16:38 -
The search for clarity regarding “clinically meaningful outcomes” in Alzheimer disease clinical trials: CLARITY-AD and Beyond
CLARITY-AD is an 18-month, double-blinded, placebo-controlled, phase 3 trial which examined the safety and efficacy of the anti-amyloid agent, lecanemab, in mild cognitive impairment and mild dementia due to A...
Citation: Alzheimer's Research & Therapy 2024 16:37 -
Relationships of change in Clinical Dementia Rating (CDR) on patient outcomes and probability of progression: observational analysis
Understanding the relationship among changes in Clinical Dementia Rating (CDR), patient outcomes, and probability of progression is crucial for evaluating the long-term benefits of disease-modifying treatments...
Citation: Alzheimer's Research & Therapy 2024 16:36 -
Impaired 24-h activity patterns are associated with an increased risk of Alzheimer’s disease, Parkinson’s disease, and cognitive decline
Sleep-wake regulating circuits are affected during prodromal stages in the pathological progression of both Alzheimer’s disease (AD) and Parkinson’s disease (PD), and this disturbance can be measured passively...
Citation: Alzheimer's Research & Therapy 2024 16:35 -
The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer’s disease
Lack of early molecular biomarkers in sporadic behavioral variants of frontotemporal dementia (bvFTD) and its clinical overlap with primary psychiatric disorders (PPD) hampers its diagnostic distinction. Synap...
Citation: Alzheimer's Research & Therapy 2024 16:34 -
Correction: Is later‑life depression a risk factor for Alzheimer’s disease or a prodromal symptom: a study using post‑mortem human brain tissue?
Citation: Alzheimer's Research & Therapy 2024 16:33 -
The impact of kidney function on plasma neurofilament light and phospho-tau 181 in a community-based cohort: the Shanghai Aging Study
The blood-based biomarkers are approaching the clinical practice of Alzheimer’s disease (AD). Chronic kidney disease (CKD) has a potential confounding effect on peripheral protein levels. It is essential to ch...
Citation: Alzheimer's Research & Therapy 2024 16:32 -
Effects of certain pre-analytical factors on the performance of plasma phospho-tau217
Pre-analytical factors can cause substantial variability in the measurements of cerebrospinal fluid (CSF) and plasma biomarkers of Alzheimer’s disease (AD). However, their effects on the performance of one of ...
Citation: Alzheimer's Research & Therapy 2024 16:31 -
Prevalence and trend of central nervous system–active medication polypharmacy among US commercially insured adults with vs without early-onset dementia: a multi-year cross-sectional study
Limited data exist on the prevalence and trend of central nervous system (CNS)-active medication polypharmacy among adults with early-onset dementia (EOD) and whether these estimates differ for adults without ...
Citation: Alzheimer's Research & Therapy 2024 16:30 -
DNA hypomethylation promotes the expression of CASPASE-4 which exacerbates inflammation and amyloid-β deposition in Alzheimer’s disease
Alzheimer’s disease (AD) is the sixth leading cause of death in the USA. It is established that neuroinflammation contributes to the synaptic loss, neuronal death, and symptomatic decline of AD patients. Accum...
Citation: Alzheimer's Research & Therapy 2024 16:29 -
Associations between cardiometabolic multimorbidity and cerebrospinal fluid biomarkers of Alzheimer’s disease pathology in cognitively intact adults: the CABLE study
Cardiometabolic multimorbidity is associated with an increased risk of dementia, but the pathogenic mechanisms linking them remain largely undefined. We aimed to assess the associations of cardiometabolic mult...
Citation: Alzheimer's Research & Therapy 2024 16:28 -
Anodal HD-tDCS on the dominant anterior temporal lobe and dorsolateral prefrontal cortex: clinical results in patients with mild cognitive impairment
Mild cognitive impairment (MCI) is a neurocognitive disorder in which the cognitive and mental abilities of humans are declined. Transcranial direct-current stimulation (tDCS) is an emerging noninvasive brain ...
Citation: Alzheimer's Research & Therapy 2024 16:27 -
Unveiling the sound of the cognitive status: Machine Learning-based speech analysis in the Alzheimer’s disease spectrum
Advancement in screening tools accessible to the general population for the early detection of Alzheimer’s disease (AD) and prediction of its progression is essential for achieving timely therapeutic intervent...
Citation: Alzheimer's Research & Therapy 2024 16:26 -
Small vessel cerebrovascular disease is associated with cognition in prospective Alzheimer’s clinical trial participants
Secondary prevention clinical trials for Alzheimer’s disease (AD) target amyloid accumulation in asymptomatic, amyloid-positive individuals, but it is unclear to what extent other pathophysiological processes,...
Citation: Alzheimer's Research & Therapy 2024 16:25 -
Differential effects of cholesterol levels on cognition according to body mass index in Parkinson’s disease
Cholesterol is an essential component of the neuronal cell membrane and is crucial for neuronal function; however, the role of cholesterol levels in Parkinson’s disease (PD) is debatable. This study investigat...
Citation: Alzheimer's Research & Therapy 2024 16:24 -
A multimodal precision-prevention approach combining lifestyle intervention with metformin repurposing to prevent cognitive impairment and disability: the MET-FINGER randomised controlled trial protocol
Combining multimodal lifestyle interventions and disease-modifying drugs (novel or repurposed) could provide novel precision approaches to prevent cognitive impairment. Metformin is a promising candidate in vi...
Citation: Alzheimer's Research & Therapy 2024 16:23 -
A nonhuman primate model with Alzheimer’s disease-like pathology induced by hippocampal overexpression of human tau
Alzheimer’s disease (AD) is one of the most burdening diseases of the century with no disease-modifying treatment at this time. Nonhuman primates (NHPs) share genetic, anatomical, and physiological similaritie...
Citation: Alzheimer's Research & Therapy 2024 16:22 -
Mild behavioral impairment in early Alzheimer’s disease and its association with APOE and BDNF risk genetic polymorphisms
Mild behavioral impairment (MBI) has been commonly reported in early Alzheimer’s disease (AD) but rarely using biomarker-defined samples. It is also unclear whether genetic polymorphisms influence MBI in such ...
Citation: Alzheimer's Research & Therapy 2024 16:21 -
A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer’s disease
Effective, disease-modifying therapeutics for the treatment of Alzheimer’s disease (AD) remain a large unmet need. Extensive evidence suggests that amyloid beta (Aβ) is central to AD pathophysiology, and Aβ ol...
Citation: Alzheimer's Research & Therapy 2024 16:20 -
Subclinical epileptiform activity in the Alzheimer continuum: association with disease, cognition and detection method
Epileptic seizures are an established comorbidity of Alzheimer’s disease (AD). Subclinical epileptiform activity (SEA) as detected by 24-h electroencephalography (EEG) or magneto-encephalography (MEG) has been...
Citation: Alzheimer's Research & Therapy 2024 16:19 -
Correction: Neuron‑derived extracellular vesicles in blood reveal effects of exercise in Alzheimer’s disease
Citation: Alzheimer's Research & Therapy 2024 16:18 -
Diet patterns and cognitive performance in a UK Female Twin Registry (TwinsUK)
Plant-based diets may provide protection against cognitive decline and Alzheimer’s disease, but observational data have not been consistent. Previous studies include early life confounding from socioeconomic c...
Citation: Alzheimer's Research & Therapy 2024 16:17 -
Plasma metabolic profiles predict future dementia and dementia subtypes: a prospective analysis of 274,160 participants
Blood-based biomarkers for dementia are gaining attention due to their non-invasive nature and feasibility in regular healthcare settings. Here, we explored the associations between 249 metabolites with all-ca...
Citation: Alzheimer's Research & Therapy 2024 16:16 -
Histone deacetylase inhibitors VPA and WT161 ameliorate the pathological features and cognitive impairments of the APP/PS1 Alzheimer’s disease mouse model by regulating the expression of APP secretases
Alzheimer’s disease (AD) is a degenerative neurological disorder. Recent studies have indicated that histone deacetylases (HDACs) are among the most prominent epigenetic therapy targets and that HDAC inhibitor...
Citation: Alzheimer's Research & Therapy 2024 16:15 -
Multi-omics and pathway analyses of genome-wide associations implicate regulation and immunity in verbal declarative memory performance
Uncovering the functional relevance underlying verbal declarative memory (VDM) genome-wide association study (GWAS) results may facilitate the development of interventions to reduce age-related memory decline ...
Citation: Alzheimer's Research & Therapy 2024 16:14 -
A single-domain antibody detects and neutralises toxic Aβ42 oligomers in the Alzheimer’s disease CSF
Amyloid-β42 (Aβ42) aggregation consists of a complex chain of nucleation events producing soluble oligomeric intermediates, which are considered the major neurotoxic agents in Alzheimer’s disease (AD). Cerebral l...
Citation: Alzheimer's Research & Therapy 2024 16:13 -
Associations of cerebrospinal fluid complement proteins with Alzheimer’s pathology, cognition, and brain structure in non-dementia elderly
Cerebrospinal fluid (CSF) complement activation is a key part of neuroinflammation that occurs in the early stages of Alzheimer’s disease (AD). However, the associations of CSF complement proteins with AD path...
Citation: Alzheimer's Research & Therapy 2024 16:12 -
Correction: Baseline structural MRI and plasma biomarkers predict longitudinal structural atrophy and cognitive decline in early Alzheimer’s disease
Citation: Alzheimer's Research & Therapy 2024 16:11 -
Diagnostic accuracy of research criteria for prodromal frontotemporal dementia
The Genetic Frontotemporal Initiative Staging Group has proposed clinical criteria for the diagnosis of prodromal frontotemporal dementia (FTD), termed mild cognitive and/or behavioral and/or motor impairment ...
Citation: Alzheimer's Research & Therapy 2024 16:10 -
Metabotropic glutamate receptor 5 (mGluR5) is associated with neurodegeneration and amyloid deposition in Alzheimer’s disease: A [18F]PSS232 PET/MRI study
Metabotropic glutamate receptor 5 (mGluR5) is involved in regulating integrative brain function and synaptic transmission. Aberrant mGluR5 signaling and relevant synaptic failure play a key role in the initial...
Citation: Alzheimer's Research & Therapy 2024 16:9 -
Associations between genetically predicted plasma protein levels and Alzheimer’s disease risk: a study using genetic prediction models
Specific peripheral proteins have been implicated to play an important role in the development of Alzheimer’s disease (AD). However, the roles of additional novel protein biomarkers in AD etiology remains elus...
Citation: Alzheimer's Research & Therapy 2024 16:8 -
Effects of APOE2 and APOE4 on brain microstructure in older adults: modification by age, sex, and cognitive status
APOE4 is the strongest genetic risk factor for sporadic Alzheimer’s disease (AD), whereas APOE2 confers protection. However, effects of APOE on neurodegeneration in cognitively intact individuals, and how these a...
Citation: Alzheimer's Research & Therapy 2024 16:7 -
Cognitive training and brain stimulation in patients with cognitive impairment: a randomized controlled trial
Repeated sessions of training and non-invasive brain stimulation have the potential to enhance cognition in patients with cognitive impairment. We hypothesized that combining cognitive training with anodal tra...
Citation: Alzheimer's Research & Therapy 2024 16:6 -
miR-129-5p as a biomarker for pathology and cognitive decline in Alzheimer’s disease
Alzheimer’s dementia (AD) pathogenesis involves complex mechanisms, including microRNA (miRNA) dysregulation. Integrative network and machine learning analysis of miRNA can provide insights into AD pathology a...
Citation: Alzheimer's Research & Therapy 2024 16:5 -
The fluorescent ligand bTVBT2 reveals increased p-tau uptake by retinal microglia in Alzheimer’s disease patients and AppNL−F/NL−F mice
Amyloid beta (Aβ) deposits and hyperphosphorylated tau (p-tau) accumulation have been identified in the retina of Alzheimer’s disease (AD) patients and transgenic AD mice. Previous studies have shown that reti...
Citation: Alzheimer's Research & Therapy 2024 16:4 -
Unraveling the intercellular communication disruption and key pathways in Alzheimer’s disease: an integrative study of single-nucleus transcriptomes and genetic association
Recently, single-nucleus RNA-seq (snRNA-seq) analyses have revealed important cellular and functional features of Alzheimer's disease (AD), a prevalent neurodegenerative disease. However, our knowledge regardi...
Citation: Alzheimer's Research & Therapy 2024 16:3 -
Digital Clock and Recall is superior to the Mini-Mental State Examination for the detection of mild cognitive impairment and mild dementia
Disease-modifying treatments for Alzheimer’s disease highlight the need for early detection of cognitive decline. However, at present, most primary care providers do not perform routine cognitive testing, in p...
Citation: Alzheimer's Research & Therapy 2024 16:2 -
Interest in genetic susceptibility testing and disclosure of AD dementia risk in cognitively normal adults: a survey study
Apolipoprotein-E (APOE) genetic testing for Alzheimer’s disease is becoming more important as clinical trials are increasingly targeting individuals carrying APOE-ε4 alleles. Little is known about the interest...
Citation: Alzheimer's Research & Therapy 2024 16:1 -
Statins and cognitive decline in patients with Alzheimer’s and mixed dementia: a longitudinal registry-based cohort study
Disturbances in brain cholesterol homeostasis may be involved in the pathogenesis of Alzheimer’s disease (AD). Lipid-lowering medications could interfere with neurodegenerative processes in AD through choleste...
Citation: Alzheimer's Research & Therapy 2023 15:220 -
Multimodal lifestyle engagement patterns support cognitive stability beyond neuropathological burden
Modifiable lifestyle behaviors account for a large proportion of dementia risk. However, the combined contributions of multidomain lifestyle patterns to cognitive aging are poorly understood, as most studies h...
Citation: Alzheimer's Research & Therapy 2023 15:221 -
The neural substrates of transdiagnostic cognitive-linguistic heterogeneity in primary progressive aphasia
Clinical variants of primary progressive aphasia (PPA) are diagnosed based on characteristic patterns of language deficits, supported by corresponding neural changes on brain imaging. However, there is (i) con...
Citation: Alzheimer's Research & Therapy 2023 15:219 -
White matter integrity is associated with cognition and amyloid burden in older adult Koreans along the Alzheimer’s disease continuum
White matter (WM) microstructural changes in the hippocampal cingulum bundle (CBH) in Alzheimer’s disease (AD) have been described in cohorts of largely European ancestry but are lacking in other populations.
Citation: Alzheimer's Research & Therapy 2023 15:218 -
Neurophysiological markers in community-dwelling older adults with mild cognitive impairment: an EEG study
Neurodegeneration and structural changes in the brain due to amyloid deposition have been observed even in individuals with mild cognitive impairment (MCI). EEG measurement is considered an effective tool beca...
Citation: Alzheimer's Research & Therapy 2023 15:217 -
A novel apoE-mimetic increases brain apoE levels, reduces Aβ pathology and improves memory when treated before onset of pathology in male mice that express APOE3
Alzheimer’s disease (AD) is characterized by cognitive dysfunction and amyloid plaques composed of the amyloid-beta peptide (Aβ). APOE is the greatest genetic risk for AD with APOE4 increasing risk up to ~ 15-fol...
Citation: Alzheimer's Research & Therapy 2023 15:216 -
NeuroEPO plus (NeuralCIM®) in mild-to-moderate Alzheimer’s clinical syndrome: the ATHENEA randomized clinical trial
NeuroEPO plus is a recombinant human erythropoietin without erythropoietic activity and shorter plasma half-life due to its low sialic acid content. NeuroEPO plus prevents oxidative damage, neuroinflammation, ...
Citation: Alzheimer's Research & Therapy 2023 15:215 -
Lipidomics profiling reveals distinct patterns of plasma sphingolipid alterations in Alzheimer’s disease and vascular dementia
Alzheimer’s disease (AD) and vascular dementia (VaD) are two of the commonest causes of dementia in the elderly. Of the myriad biomolecules implicated in dementia pathogenesis, sphingolipids have attracted rel...
Citation: Alzheimer's Research & Therapy 2023 15:214 -
Proof-of-concept recall-by-genotype study of extremely low and high Alzheimer’s polygenic risk reveals autobiographical deficits and cingulate cortex correlates
Genome-wide association studies demonstrate that Alzheimer’s disease (AD) has a highly polygenic architecture, where thousands of independent genetic variants explain risk with high classification accuracy. Th...
Citation: Alzheimer's Research & Therapy 2023 15:213 -
Predicting positron emission tomography brain amyloid positivity using interpretable machine learning models with wearable sensor data and lifestyle factors
Developing a screening method for identifying individuals at higher risk of elevated brain amyloid burden is important to reduce costs and burden to patients in clinical trials on Alzheimer’s disease or the cl...
Citation: Alzheimer's Research & Therapy 2023 15:212 -
The age-specific comorbidity burden of mild cognitive impairment: a US claims database study
Identifying individuals with mild cognitive impairment (MCI) who are likely to progress to Alzheimer’s disease and related dementia disorders (ADRD) would facilitate the development of individualized preventio...
Citation: Alzheimer's Research & Therapy 2023 15:211
Follow
- ISSN: 1758-9193 (electronic)